Основные механизмы влияния метаболического синдрома на риск возникновения и прогноз течения рака молочной железы (обзор литературы)
https://doi.org/10.17650/1994-4098-2013-0-1-2-45-51
Аннотация
Рак молочной железы (РМЖ) и метаболический синдром остаются одними из наиболее актуальных проблем современной меди- цины во всем мире. В данной работе освещены молекулярные механизмы, которые лежат в основе негативного влияния метабо- лического синдрома на риск возникновения и прогноз течения РМЖ. Лучшее понимание этих механизмов поможет оптимизировать профилактику и лечение РМЖ у больных с метаболическим синдромом.
Об авторах
И. Б. Щепотин
Национальный медицинский университет имени А.А. Богомольца, Киев
Украина
Украина
А. С. Зотов
Национальный медицинский университет имени А.А. Богомольца, Киев
Украина
Украина
Р. В. Любота
Национальный медицинский университет имени А.А. Богомольца, Киев
Украина
Украина
Н. Ф. Аникусько
Киевский городской клинический онкологический центр
Украина
Украина
И. И. Любота
Киевский городской клинический онкологический центр
Украина
Украина
Список литературы
1. World Cancer Report. International Agency for Research on Cancer. 2008. http://www.iarc.fr/en/publications/pdfs-online/prev/ handbook7/index.php. Retrieved 2011-02-26.
2. International Diabetes Federation Epidemiology Task Force Consensus Group. The IDF consensus world wide definition of the metabolic syndrome. International Diabetes Federation. Brussels, 2005. (Available at: www.idf.org/webdata/docs/IDF Metasyndrome definition.pdf).
3. Agnoli C., Berrino F., Abagnato C.A. et al. Metabolic syndrome and postmenopausal breast cancer in the ORDET cohort: a nested case-control study. Nutr Metab Cardiovasc Dis 2010;20(1):41–8.
4. Lipscombe L.L., Goodwin P.J., Zinman B. et al. The impact of diabetes on survival following breast cancer. Breast Cancer Res Treat 2008;109(2):389–95.
5. Pasanisi P., Berrino F., De Petris M. et al. Metabolic syndrome as a prognostic factor for breast cancer recurrences. Int J Cancer 2006;119(1):236–8.
6. Щепотин И.Б., Зотов А.С., Любота И.И., Любота Р.В. Клинические
7. и лабораторные показатели синдрома ин- сулинорезистентности как факторы прогноза течения рака молочной железы. Научн вестн Нац мед ун-та им.
8. А.А. Богомольца 2007;(2):168–72.
9. Grodin J.M., Siiteri P.K., MacDonald P.C. Source of estrogen production in postmenopausal women. J Clin Endocrinol Metab 1973;36(2):207–14.
10. van Landeghem A.A., Poortman J., Nabuurs M., Thijssen J.H. Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res 1985;45(6):2900–6.
11. Bulun S.E., Simpson E.R. Breast cancer and expression of aromatase in breast adipose tissue. Trends Endocrinol Metab 1994;5(3):113–20.
12. Берштейн Л.М. Онкоэндокринология: Традиции, современность и перспективы. СПб.: Наука, 2004. 343 с.
13. Giovannucci E., Harlan D.M., Archer M.C. et al. Diabetes and cancer: a consensus report. CA Cancer J Clin 2010;60(4):207–21.
14. Michels K.B., Solomon C.G., Hu F.B. et al. Type 2 diabetes and subsequent incidence of breast cancer in the Nurses’ Health Study. Diabetes Care 2003;26(6):1752–8.
15. Goodwin P.J., Ennis M., Pritchard K.I. et al. Fasting insulin and outcome in early- stage breast cancer: results of a prospective cohort study. J Clin Oncol 2002;20(1):42–51.
16. Grimberg A., Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol 2000;183(1):1–9.
17. Moschos S.J., Mantzoros C.S. The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology 2002;63(4):317–32.
18. Sachdev D., Yee D. The IGF system and breast cancer. Endocr Relat Cancer 2001;8(3):197–209.
19. Clarke R.B., Howell A., Anderson E. Type I insulin-like growth factor receptor gene expression in normal human breast tissue treated with oestrogen and progesterone. Br J Cancer 1997;75(4):251–7.
20. McTiernan A., Rajan K.B., Tworoger S.S. et al. Adiposity and sex hormones in postmenopausal breast cancer survivors. J Clin Oncol 2003;21(10):1961–6.
21. Zeleniuch-Jacquotte A., Shore R.E., Koenig K.L. et al. Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study. Br J Cancer 2004;90(1):153–9.
22. Fortunati N., Fissore F., Fazzari A. et al. Estradiol induction of cAMP in breast cancer cells is mediated by foetal calf serum (FCS) and sex hormone-binding globulin (SHBG). J Steroid Biochem Mol Biol 1999;70(1–3):73–80.
23. Catalano M.G., Frairia R., Boccuzzi G., Fortunati N. Sex hormone-binding globulin antagonizes the anti-apoptotic effect of estradiol in breast cancer cells. Mol Cell Endocrinol 2005;230(1):31–7.
24. Manabe Y., Toda S., Miyazaki K., Sugihara H. Mature adipocytes, but not preadipocytes, promote the growth of breast carcinoma cells in collagen gel matrix culture through cancer-stromal cell interactions.
25. J Pathol 2003;201(2):221–8.
26. Iyengar P., Combs T.P., Shah S.J et al. Adipocyte-secreted factors synergistically promote mammary tumorigenesis through induction of anti-apoptotic transcriptional programs and proto-oncogene stabilization. Oncogene 2003;22(41):6408–23.
27. Hu X., Juneja S.C., Maihle N.J., Cleary M.P. Leptin – a growth factor in normal and malignant breast cells and for normal mammary gland development. J Natl Cancer Inst 2002;94(22):1704–11.
28. Laud K., Gourdou I., Pessemesse L. et al. Identification of leptin receptors in human breast cancer: functional activity in the T47-D breast cancer cell line. Mol Cell Endocrinol 2002;188(1–2):219–26.
29. Dieudonne M.N., Machinal-Quelin F., Serazin-Leroy V. et al. Leptin mediates a proliferative response in human MCF7 breast cancer cells. Biochem Biophys Res Commun 2002;293(1):622–8.
30. Okumura M., Yamamoto M., Sakuma H. et al. Leptin and high glucose stimulate cell proliferation in MCF-7 human breast cancer cells: reciprocal involvement of PKC-alpha and PPAR expression. Biochim Biophys Acta 2002;1592(2):107–16.
31. Bjorbaek C., Uotani S., da Silva B. et al. Divergent signaling capacities of the long and short isoforms of the leptin receptor. J Biol Chem 1997;51(272):32686–95.
32. Andò S., Catalano S. The multifactorial role of leptin in driving the breast cancer microenvironment. Nat Rev Endocrinol 2012;8(5):263–75.
33. Xia X.H., Gu J.C., Bai Q.Y. et al. Overexpression of leptin and leptin receptors in breast cancer positively correlates with clinicopathological features. Chin Med J (Engl) 2009;122(24):3078–81.
34. Jarde T., Caldefie-Chezet F., Damez M. et al. Leptin and leptin receptor involvement in cancer development: a study on human primary breast carcinoma. Oncol Rep 2008;19(4):905–11.
35. Ouchi N., Kihara S., Funahashi T. et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003;107(5):671–4.
36. Yamauchi T., Kamon J., Waki H. et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7(8):941–6.
37. Mantzoros C., Petridou E., Dessypris N. et al. Adiponectin and breast cancer risk.
38. J Clin Endocrinol Metab 2004;89(3):1102–7.
39. Miyoshi Y., Funahashi T., Kihara S. et al. Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res 2003;9(15):5699–704.
40. Igata M., Motoshima H., Tsuruzoe K. et al. Adenosine monophosphate-activated protein kinase suppresses vascular smooth muscle cell proliferation through the inhibition of cell cycle progression. Circ Res 2005;97(7):837–44.
41. Ouedraogo R., Wu X., Xu S.Q. et al. Adiponectin suppression of high-glucose- induced reactive oxygen species in vascular endothelial cells: evidence for involvement of a cAMP signaling pathway. Diabetes 2006;55(6):1840–6.
42. Brakenhielm E., Veitonmäki N., Cao R. et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase- mediated endothelial cell apoptosis. Proc Natl Acad Sci USA 2004;101(8):2476–81.
43. Carswell E.A., Old L.J, Kassel R.L. et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975;72(9):3666–70.
44. Kulbe H., Thompson R., Wilson J.L. et al. The inflammatory cytokine tumor necrosis factor-α generates an autocrine tumor- promoting network in epithelial ovarian cancer cells. Cancer Res 2007;67(2):585–92.
45. Davies F.E., Rollinson S.J., Rawstron A.C. et al. High-producer haplotypes of tumor necrosis factor α and lymphotoxin α are associated with an increased risk of myeloma and have an improved progression-free survival after treatment. J Clin Oncol 2000;18(4):2843–51.
46. Chen G., Goeddel D.V. TNF-R1 signaling: a beautiful pathway. Science 2002;296(5573):1634–5.
47. Balkwill F. TNF-α in promotion and progression of cancer. Cancer Metastasis Rev 2006;25(3):409–16.
48. Il'yasova D., Colbert L.H., Harris T.B. et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev 2005;14(10):2413–8.
49. Kishimoto T. Interleukin-6: from basic science to medicine – 40 years in immunology. Annu Rev Immunol 2005;23(1):1–21.
50. Schafer Z.T., Brugge J.S. IL-6 involvement in epithelial cancers. J Clin Invest 2007;117(12):3660–3.
51. Purohit A., Newman S.P., Reed M.J. The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer. Breast Cancer Res 2002;4(2):65–9.
52. Bachelot T., Ray-Coquard I., Menetrier- Caux C. et al. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br J Cancer 2003;88(11):1721–6.
53. Helle S.I., Holly J.M., Tally M. et al. Influence of treatment with tamoxifen and change in tumor burden on the IGF-system in breast cancer patients. Int J Cancer 1996;69(4):335–9.
54. Wolf I., Sadetzki S., Catane R. et al. Diabetes mellitus and breast cancer. Lancet Oncol 2005;6(2):103–11.
55. Goodwin P.J., Stambolic V., Lemieux J. et al. Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat 2011;126(1):215–20.
56. Jalving M., Gietema J.A., Lefrandt J.D. et al. Metformin: taking away the candy for cancer? Eur J Cancer 2010;46(13):2369–80.
57. Otvos L.J., Kovalszky I., Scolaro L. et al. Peptide-based leptin receptor antagonists for cancer treatment and appetite regulation. Biopolymers 2011;96(2):117–25.
58. Terry M.B., Gammon M.D., Zhang F.F. et al. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 2004;291(20):2433–40.
59. Zhang Y., Coogan P.F., Palmer J.R. et al. Use of nonsteroidal anti-inflammatory drugs and risk of breast cancer: the Case-Control Surveillance Study revisited. Am J Epidemiol 2005;162(2):165–70.
60. Garcia Rodriguez L.A., Gonzalez-Perez A. Risk of breast cancer among users of aspirin and other anti-inflammatory drugs. Br J Cancer 2004;91(3):525–9.
61. DuBois R.N. Aspirin and breast cancer prevention: the estrogen connection. JAMA 2004;291(20):2488–9.
62. McTiernan A., Irwin M., Von Gruenigen V. Weight, physical activity, diet, and prognosis in breast and gynecologic cancers. J Clin Oncol 2010;28(26):4074–80. 59. Maeso Fortuny M.C., Brito Díaz B., Cabrera de León A. Leptin, estrogens and cancer. Mini Rev Med Chem 2006;6(8):897–907.
Рецензия
Для цитирования:
Щепотин И.Б., Зотов А.С., Любота Р.В., Аникусько Н.Ф., Любота И.И. Основные механизмы влияния метаболического синдрома на риск возникновения и прогноз течения рака молочной железы (обзор литературы). Опухоли женской репродуктивной системы. 2013;(1-2):45-51. https://doi.org/10.17650/1994-4098-2013-0-1-2-45-51
For citation:
Schepotin I.B., Zotov A.S., Lyubota R.V., Anikusko N.F., Lyubota I.I. The basic mechanisms the influence of metabolic syndrome on the risk and prognosis of breast cancer (review). Tumors of female reproductive system. 2013;(1-2):45-51. (In Russ.) https://doi.org/10.17650/1994-4098-2013-0-1-2-45-51
Просмотров:
671
Послать статью по эл. почте 